On June 18, 2019, we established the cell therapy center in China Medical University Hospital to promote clinical services related to the Regulations of special Medical Techniques, and actively develop and launch a number of multi-center clinical trials related to cell therapy.

The latest clinical follow-up results of various cell therapies under the Regulations of special Medical Techniques have been presented in a series of special reports at the Spring Meeting of the Taiwan Medical Association in May this year, and these results will be  written in separate papers.

The clinical service operation of this cell therapy center has always been the learning object of many domestic medical institutions, and the R&D team is constantly innovating and actively conducting multi-center clinical trials of Phase I or Phase II, in order to solve the unmet clinical needs. In addition, we have also set up the international collaboration with  Prof. Tseng in Harvard University, Boston for BAT men, Prof. Kawamoto in Kyoto for iPS-TCRT, and Prof. Wang in Melbourne for PD-1/TK iPS to develop advanced cell therapy for both cancer and regenerative medicine.  

We adhere to problem-oriented learning, focus on practical issues, and encourage doctors to take the initiative in lifelong learning, critical thinking, and improve problem-solving skills. Based on this belief, we lead the continuous progress of medical care.

All colleagues uphold enthusiasm, follow the hospital's policies and work hard to implement the medical center's purpose of service, teaching and research.